Amgen Inc. (NASDAQ:AMGN) Shares Purchased by 1ST Source Bank

1ST Source Bank boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 4.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,988 shares of the medical research company’s stock after buying an additional 116 shares during the period. 1ST Source Bank’s holdings in Amgen were worth $779,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Legacy Investment Solutions LLC acquired a new position in shares of Amgen during the third quarter valued at $29,000. Centricity Wealth Management LLC acquired a new position in shares of Amgen in the 4th quarter valued at $25,000. Synergy Investment Management LLC acquired a new position in shares of Amgen in the 4th quarter valued at $34,000. Atala Financial Inc acquired a new position in shares of Amgen in the 4th quarter valued at $34,000. Finally, Heck Capital Advisors LLC acquired a new position in shares of Amgen in the 4th quarter valued at $36,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Amgen

In other Amgen news, EVP David M. Reese sold 25,225 shares of the company’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the company’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares in the company, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on AMGN shares. Redburn Partners decreased their price objective on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Truist Financial lowered their target price on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research note on Wednesday, January 8th. UBS Group reaffirmed a “hold” rating on shares of Amgen in a research note on Wednesday, February 12th. Citigroup reaffirmed a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Finally, Leerink Partners lowered their target price on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus price target of $314.04.

Amgen Stock Up 1.1 %

Shares of AMGN stock opened at $317.17 on Tuesday. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The firm has a market cap of $170.39 billion, a PE ratio of 42.01, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The stock has a 50 day moving average of $292.99 and a 200-day moving average of $299.02. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.00%. Amgen’s payout ratio is 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.